早在1971年Folkman即提出抗血管生成能治疗恶性肿瘤的假说,30多年的实验及临床研究结果显示,以血管内皮生长因子(vascular endothelial growth factor,VEGF)及其受体为靶点的肿瘤生物治疗具有良好的耐受性和明显的疗效,我们即将迎来以VEGF为基础的肾癌分子靶向治疗时代。现将有 As early as 1971, Folkman proposed the hypothesis that anti-angiogenesis can treat malignant tumors. More than 30 years of experimental and clinical studies have shown that tumor organisms that target the vascular endothelial growth factor (VEGF) and its receptors Treatment has good tolerability and significant effect, we are about to usher in the era of VEGF-based molecular targeted therapy of renal cell carcinoma. Now there